Lilly Halts Development of Semagacestat for Alzheimer’s Disease Based on Preliminary Results of Phase III Clinical …
Eli Lilly and Company will halt development of semagacestat, a gamma secretase inhibitor being studied as a potential treatment for Alzheimer’s disease, because preliminary results from two ongoing long-term Phase III studies showed it did not slow disease progression and was associated with worsening of clinical measures of cognition and the ability to perform activities of daily living.
Read more on PR Newswire via Yahoo! Finance
Popular Posts:
- Summary Box: Lilly halts Alzheimer’s drug
- Geron shares rise on stem cell study
- Geron shares rise on stem cell study
- Bristol-Myers reports diabetes drug results
- CI-Now™ Brings Clinical Integration to Health Care Providers